Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 4/20 | 0.60 |
| ▸ | F2 | P00734 | 2/20 | 0.57 |
| ▸ | TERT | O14746 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.47 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.46 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14389953 | 1.00 | DTYMK (0.60) | DTYMKF2TERTPOLBENPP1 | |
| SCHEMBL13326136 | 1.00 | DTYMK (0.60) | DTYMKF2TERTPOLBENPP1 | |
| SCHEMBL10034039 | 1.00 | DTYMK (0.60) | DTYMKF2TERTPOLBENPP1 | |
| SCHEMBL14389886 | 1.00 | DTYMK (0.60) | DTYMKF2TERTPOLBENPP1 | |
| SCHEMBL26189527 | 0.96 | F2 (0.64) | DTYMKF2TERTPOLBENPP1 | |
| SCHEMBL26189524 | 0.96 | F2 (0.64) | DTYMKF2TERTPOLBENPP1 | |
| SCHEMBL21504636 | 0.96 | F2 (0.64) | DTYMKF2TERTPOLBENPP1 | |
| SCHEMBL21489387 | 0.96 | F2 (0.64) | DTYMKF2TERTPOLBENPP1 | |
| SCHEMBL30301232 | 0.94 | DTYMK (0.65) | DTYMKF2TERTPOLBENPP1 | |
| SCHEMBL29401735 | 0.94 | DTYMK (0.65) | DTYMKF2TERTPOLBENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773098-B2 | Solid forms of a toll-like receptor modulator | GILEAD SCIENCES, INC. (US) | 2023-10-03 | — | — | US | claimed |
| CN-122036801-A | Crystalline forms of tenofovir alafenamide | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-3870566-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4234030-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260028603-A1 | ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | PRECISION BIOSCIENCES, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-12522570-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4667477-A2 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12486271-B2 | Solid forms of a toll-like receptor modulator | GILEAD SCIENCES, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20220143061-A1 | 3'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2022-05-12 | — | — | US | disclosed |
| EP-3990476-A1 | FLT3L-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-20220117952-A1 | METHODS FOR TREATING HEPATITIS B VIRUS INFECTIONS USING NS5A, NS5B OR NS3 INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11292812-B2 | 3′3′-cyclic dinucleotides | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2022-04-05 | — | — | US | disclosed |
| EP-3972695-A1 | SUBSTITUTED EXO-METHYLENE-OXINDOLES WHICH ARE HPK1/MAP4K1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-114245807-A | FLT3L-FC fusion proteins and methods of use | 吉利德科学公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20220073473-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220049021-A1 | FLT3L-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
| US-11236085-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073473-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | DTYMK 1307/4885F2 4608/4885TERT 4237/4885 |
| US-20220143061-A1 | 3'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | STING1, CGAS, IRF3 | DTYMK 104/4885F2 3420/4885TERT 2067/4885 |
| US-12486271-B2 | Solid forms of a toll-like receptor modulator | TLR4, TLR3, TLR6 | DTYMK 1093/4885F2 2633/4885TERT 4559/4885 |
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | PNP, TYMP, NME2 | DTYMK 60/4885F2 2356/4885TERT 2354/4885 |
| US-20220117952-A1 | METHODS FOR TREATING HEPATITIS B VIRUS INFECTIONS USING NS5A, NS5B OR NS3 INHIBITORS | HAVCR2, EIF2AK2, HPN | DTYMK 2231/4885F2 4441/4885TERT 1656/4885 |
| US-11773098-B2 | Solid forms of a toll-like receptor modulator | TLR4, TLR3, TLR6 | DTYMK 1093/4885F2 2633/4885TERT 4559/4885 |
| US-11292812-B2 | 3′3′-cyclic dinucleotides | STING1, CGAS, MAVS | DTYMK 24/4885F2 4672/4885TERT 2810/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | DTYMK 3343/4885F2 4847/4885TERT 1253/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | DTYMK 115/4885F2 4642/4885TERT 2753/4885 |
| US-11236085-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | DTYMK 561/4885F2 3949/4885TERT 242/4885 |
| US-20260028603-A1 | ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | HAVCR2, PNP, ADAR | DTYMK 448/4885F2 1115/4885TERT 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.